Reversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticle-facilitated delivery of target siRNAs

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 2473-2481

  Li, Yong Tsuey ^a   Chua, Ming Jang ^a   Kunnath, Anil Philip ^a   Chowdhury, Ezharul Hoque ^a,b  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^b MONASH UNIVERSITY MALAYSIA   (Malaysia)

Author keywords

ABC transporter; Breast cancer; Carbonate apatite; Chemosensitivity; Gene expression; Multidrug resistance; SiRNA; Transfection

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ABC TRANSPORTER; CISPLATIN; CYCLIN B1; DOXORUBICIN; NANOPARTICLE; PACLITAXEL; SMALL INTERFERING RNA;

ARTICLE; ATP BINDING CASSETTE TRANSPROTER B1 GENE; ATP BINDING CASSETTE TRANSPROTER G2 GENE; ATP BINDING CASSETTE TRANSPROTER GENE; BREAST CANCER; CANCER CELL CULTURE; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; CYCLINE B1 GENE; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; GENE DELIVERY SYSTEM; GENE EXPRESSION PROFILING; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; ONCOGENE; PH MEASUREMENT; RNA SEQUENCE; SEQUENCE ANALYSIS; TUMOR GENE;

APATITES; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE SILENCING; HUMANS; MCF-7 CELLS; NANOPARTICLES; RNA, SMALL INTERFERING;

EID: 84866541545     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S30500     Document Type: Article

References (46)

1. Moulder S, Hortobagyi GN. Advances in the treatment of breast cancer. Clin Pharmacol Ther. 2008;83(1):26-36.
2. Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist. 2001;6(2):133-146.
3. Hortobagyi GN. Treatment of breast cancer. N Engl J Med. 1998;339(18):974-984.
4. Tubiana-Hulin M. How to maximize the efficacy of taxanes in breast cancer. Cancer Treat Rev. 2005;31 Suppl 4:S3-S9.
5. Fisher B, Redmond C, Wickerham DL, etal. Doxorubicin-containing regimens for the treatment of stage II breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol. 1989;7(5):572-582.
6. Nabholtz JM, Falkson C, Campos D, etal. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol. 2003;21(10):968-975.
7. Henderson IC, Berry DA, Demetri GD, etal. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21(6):976-983.
8. Burger H, Foekens JA, Look MP, etal. RNA expression of breast cancer resistance protein, lung resistance related protein, multi-drug resistance gene-1in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res. 2003;9(2):827-836.
9. Modok S, Mellor HR, Callaghan R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol. 2006;6(4):350-354.
10. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. 1999;39:361-398.
11. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2010;5(3):219-230.
12. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochem Biophys Acta. 1976;455(1):152-162.
13. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst. 1977;89(13):917-931.
14. Leonessa F, Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer. 2003;10:43-73.
15. Kröger N, Achterrath W, Hegewisch-Becker S, Mross K, Zander AR. Current options in treatment of anthracycline-resistant breast cancer. Cancer Treat Rev. 1999;25(5):279-291.
16. Tsukamoto F, Shiba E, Taguchi T, etal. Immunohistochemical detection of P-glycoprotein in breast cancer and its significance as a prognostic factor. Breast Cancer. 1997;4(4):259-263.
17. Doyle LA, Yang W, Abruzzo LV, etal. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A. 1998;95(26):15665-15670.
18. Robey RW, To KK, Polgar O, etal. ABCG2: a perspective. Adv Drug Deliv Rev. 2009;61(1):3-13.
19. Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev. 2009;61(1):26-33.
20. Wu CP, Calcagno AM, Ambudkar SV. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol. 2008;1(1):93-105.
21. Bartlett NL, Lum BL, Fisher GA, etal. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol. 1994;12(4):835-842.
22. Boote DJ, Dennis IF, Twentyman PR, etal. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol. 1996;14(2):610-618.
23. Giaccone G, Linn SC, Welink J, etal. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833in combination with doxorubicin in patients with solid tumors. Clin Cancer Res. 1997;3(11):2005-2015.
24. Tiwari AK, Sodani K, Chen ZS. Current advances in modulation of ABC transporter-mediated multidrug resistance in cancer. Int J Toxicol Pharmcol Res. 2009;1:1-6.
25. Shi Z, Liang YJ, Chen ZS, etal. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol Ther. 2006;5(1):39-47.
26. Liu C, Qureshi IA, Ding X, etal. Modulation of multidrug resistance gene (MDR-1) with antisense oligodeoxynucleotides. Clin Sci (Lond). 1996;91(1):93-98.
27. Alahari SK, DeLong R, Fisher MH, Dean NM, Viliet P, Juliano RL. Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression. J Pharmacol Exp Ther. 1998;286(1): 419-428.
28. Stuart DD, Kao GY, Allen TM. A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1. Cancer Gene Ther. 2000;7(3):466-475.
29. Kobayashi H, Dorai T, Holland JF, Ohnuma T. Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1(PGY1) ribozyme. Cancer Res. 1994;54(5):1271-1275.
30. Holm PS, Scanlon KJ, Dietel M. Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme. Br J Cancer. 1994;70(2):239-243.
31. Gao Z, Fields JZ, Boman BM. Tumor-specific expression of anti-MDR1 ribozyme selectively restores chemosensitivity in multidrug-resistant colon-adenocarcinoma cells. Int J Cancer. 1999;82(3):346-352.
32. Chowdhury EH. Strategies for tumor-directed delivery of siRNA. Expert Opin Drug Deliv. 2011;8(3):389-401.
33. Wu H, Hait WN, Yang JM. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res. 2003;63(7):1515-1519.
34. Ee PL, He X, Ross DD, Beck WT. Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference. Mol Cancer Ther. 2004;3(12):1577-1583.
35. Stanislaus A, Hossain S, Chua MJ, etal. Fabrication and intracellular delivery of siRNA/carbonate apatite nano-composites for effective knockdown of cyclin B1gene. Drugs and Therapy Studies. 2011;1:e8. DOI: 10.4081/dts.2011.e8.
36. Hossain S, Stanislaus A, Chua MJ, etal. Carbonate apatite-facilitated intracellularly delivered siRNA for efficient knockdown of functional genes. J Control Release. 2010;147(1):101-108.
37. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2011;411(6836):494-498.
38. Harborth J, Elbashir SM, Bechert K, Tuschl T, Weber K. Identification of essential genes in cultured mammalian cells using small interfering RNAs. J Cell Sci. 2001;114(Pt 24):4557-4565.
39. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987;47(4):936-942.
40. Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci U S A. 1998;95(12):7024-7029.
41. Johnstone RW, Cretney E, Smyth MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood. 1999;93(3):1075-1085.
42. Pallis M, Russell N. P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Blood. 2000;95(9):2897-2904.
43. Xu D, Kang H, Fisher M, Juliano RL. Strategies for inhibition of MDR1gene expression. Mol Pharmacol. 2004;66(2):268-275.
44. Cohen D, Yang CP, Horwitz SB. The products of the mdr1a and mdr1b genes from multidrug resistant murine cells have similar degradation rates. Life Sci. 1990;46(7):489-495.
45. Richert ND, Aldwin L, Nitecki D, Gottesman MM, Pastan I. Stability and covalent modification of P-glycoprotein in multidrug-resistant KB cells. Biochemistry. 1988;27(20):7607-7613.
46. Akhtar S, Benter IF. Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest. 2007;117(12):3623-3632.